BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
-4.13%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$1.23B
AUM Growth
+$1.23B
(-3.6%)
Cap. Flow
+$35.6M
Cap. Flow
% of AUM
2.89%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
3
Reduced
2
Closed
–
Top Buys
| 1 |
STAAR Surgical
STAA
|
$28.3M |
| 2 |
IMDX
Insight Molecular Diagnostics Inc. Common Stock
IMDX
|
$15.8M |
| 3 |
Olo Inc
OLO
|
$10.8M |
| 4 |
Lineage Cell Therapeutics
LCTX
|
$3.57M |
Top Sells
| 1 |
Axon Enterprise
AXON
|
$13.9M |
| 2 |
iShares Russell 2000 ETF
IWM
|
$8.98M |
Sector Composition
| 1 | Consumer Staples | 39.33% |
| 2 | Industrials | 29.66% |
| 3 | Healthcare | 22.47% |
| 4 | Technology | 0.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Monster Beverage
MNST
$60.9B
| $485M | 39.33% | 8,295,690 | – | – |
|
|
2
Axon Enterprise
AXON
$58.7B
| $366M | 29.66% | 696,075 -26,346 | -4% | -$13.9M |
|
|
3
STAAR Surgical
STAA
$1.36B
| $220M | 17.79% | 12,455,264 +1,606,633 | +15% | +$28.3M |
|
|
4
iShares Russell 2000 ETF
IWM
$67B
| $94.7M | 7.67% | 474,920 -45,000 | -9% | -$8.98M |
|
|
IMDX
5
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $34.9M | 2.83% | 11,410,100 +5,165,695 | +83% | +$15.8M |
|
|
6
Lineage Cell Therapeutics
LCTX
$267M
| $22.4M | 1.81% | 49,560,992 +7,894,737 | +19% | +$3.57M |
|
|
7
Olo Inc
OLO
$1.74B
| $10.8M | 0.87% | +1,782,334 | New | +$10.8M |
|
8
Serina Therapeutics
SER
$54.5M
| $483K | 0.04% | 85,219 | – | – |
|